Latest news with #Arterial
Yahoo
22-05-2025
- Health
- Yahoo
Pulmonary Arterial Hypertension Market to Hit USD 12.18 Billion By 2032, Driven by Advancements in Drug Development and Growing Awareness
Rising R&D investments, FDA approvals, and increasing awareness drive U.S. Pulmonary Arterial Hypertension Market to USD 3.95 Billion by 2032, with North America holding 38.21% global market share. Austin, May 22, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Pulmonary Arterial Hypertension Market size was valued at USD 7.91 billion in 2024 and is expected to grow to USD 12.18 billion by 2032, at a CAGR of 5.60% during the 2025–2032 forecast period. Rare and fatal, pulmonary arterial hypertension nonetheless inspires pharmaceutical innovation, particularly with government backing for orphan drug development, better diagnostics, and targeted therapies. Early diagnosis, availability of sophisticated medicines, and robust clinical research infrastructure are mostly driving the significant expansion in the PAH industry observed in the United States. With a CAGR of 5.36%, the U.S. Pulmonary Arterial Hypertension Market is expected to rise to USD 3.95 billion by 2032 from USD 2.61 billion in 2024. Supported by FDA approvals for PAH-targeted therapies, the existence of important pharmaceutical actors, and major public health funding toward rare illness a Sample Report of Pulmonary Arterial Hypertension Market@ Major Players Analysis Listed in this Report are: Johnson & Johnson United Therapeutics Corporation Bayer AG Gilead Sciences, Inc. Merck & Co., Inc. Novartis AG AbbVie Inc., Acceleron Pharma, Inc. Arena Pharmaceuticals, Inc. Sandoz and other players. Pulmonary Arterial Hypertension Market Report Scope Report Attributes Details Market Size in 2024 US$ 7.91 billion Market Size by 2032 US$ 12.18 billion CAGR CAGR of 5.60% From 2025 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By drug class Leading drug class in the PAH sector, prostacyclin and prostacyclin analogues accounted for 48.10% of the global market share in 2024. Crucially, in controlling severe instances, these drugs dilate pulmonary arteries and reduce platelet aggregation. Among common medications in this group are Iloprost, Treprostinil, and Epoprostenol. Though clinically beneficial, they may need constant infusion, which can be difficult for patients. On the other hand, the development of oral and inhalable formulations recently has increased patient compliance and expanded the attractiveness of this therapeutic class. Anticipated to further increase the dominance of this market is the significant investments pharmaceutical companies are making in developing next-generation prostacyclin medicines with longer half-lives and more flexible dosing schedules. By Type Branded medications accounted for 68.12% of the global PAH market in 2024. Strong patent portfolios and excellent efficacy of branded treatments as Opsumit, Adempas, Letairis, and Tracleer, help to explain this dominance. Supported by thorough clinical studies, the ongoing physician inclination for these reliable drugs guarantees constant demand. Moreover, new branded drugs under development gain from orphan drug classification and market exclusiveness, therefore postponing the arrival of generics. Personalized medicine tactics and fixed-dose combinations are also becoming more popular in the pharmaceutical scene, which encourages the use of branded drugs even more than generic ones. Still, the trend toward generic adoption may increase when many important patents expire by the end of the decade; branded pharmaceuticals are predicted to lead the market over the forecast period. By Route of Administration With 52.11% of the PAH market share, the oral segment dominated the PAH market in 2024. Compared to intravenous or subcutaneous therapies, oral drugs are chosen for their simplicity of use, improved patient compliance, and economy of expense. Especially recommended for people in early to moderate illness stages are phosphodiesterase-5 inhibitors (PDE5i) and oral endothelin receptor antagonists (ERAs). New developments such as combo treatments and extended-release tablets are broadening the segment even more. This segment is expected to keep its dominance through 2032 as businesses keep enhancing the bioavailability and tolerance of oral medicines, especially for long-term PAH control. Buy a Single-User PDF of Pulmonary Arterial Hypertension Market Analysis & Outlook Report 2024-2032@ Pulmonary Arterial Hypertension Market Segmentation By Drug Class Endothelin Receptor Antagonists (ERAs) PDE-5 Inhibitors Prostacyclin and Prostacyclin Analogs SGC Stimulators By Type Branded Generics By Route of Administration Oral Intravenous/ subcutaneous Inhalational Regional analysis With a 38.21% share in 2024, North America led the global pulmonary arterial hypertension market. Strong presence of big pharmaceutical players, extensive healthcare infrastructure, and solid reimbursement rules help the area thrive. Accelerating drug approvals and supporting clinical studies, the U.S. National Institutes of Health (NIH) and the FDA have greatly helped rare disease treatment development. Furthermore, supporting market growth is the growing senior population of the area, more vulnerable to pulmonary disorders. Driven by rising patient awareness, government funding for rare diseases, and improvements in diagnostic imaging, Europe boasts a sizable market share. Additionally, pushing rapid approval schemes for PAH treatments is the European Medicines Agency (EMA). larger urban pollution, a larger patient pool, and increasing access to healthcare in nations such as China and India would likely cause the Asia-Pacific region is grow with the fastest CAGR throughout the projection period. In low-income nations, however, poor knowledge and expensive treatment expenses still present difficulties. Need Any Customization Research on Pulmonary Arterial Hypertension Market, Enquire Now@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence (2024) 5.2 Drug Utilization and Prescription Patterns (2024), by Region 5.3 Treatment Adoption Rate and Patient Compliance (2020–2032) 5.4 Healthcare Expenditure on PAH Management (2024), by Region and Payer Type 6. Competitive Landscape 7. Pulmonary Arterial Hypertension Market by Drug Class 8. Pulmonary Arterial Hypertension Market by Type 9. Pulmonary Arterial Hypertension Market by Route of Administration 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Related Reports Aerosol Drug Delivery Devices Market to Soar to $80.43 Billion by 2032 at 13.19% CAGR Heparin Market to Hit $9.61 Billion by 2031 with 2.8% CAGR Growth Respiratory Care Devices Market Set to Reach $43.35 Billion by 2032, Growing at 7.7% CAGR About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Sign in to access your portfolio
Malaysian Reserve
01-05-2025
- Business
- Malaysian Reserve
Synhale Therapeutics Acquires Telaglenastat, Accelerates Development for Pulmonary Hypertension Treatment
PITTSBURGH and BOSTON, May 1, 2025 /PRNewswire/ — Synhale Therapeutics Inc. (Synhale), a virtual, clinical-stage biotech company committed to transforming Pulmonary Hypertension (PH), announced the acquisition of Telaglenastat (CB-839), the first-in-class glutaminase inhibitor. Synhale is advancing into a Phase 2 clinical program across PH Groups 1-4. 'This acquisition represents a unique opportunity to rapidly deliver clinical data addressing a disease with high mortality and substantial market potential,' said Chad D. Holland, President & CEO of Synhale. 'Leveraging Telaglenastat's prior human clinical experience, our capital-efficient model aims to accelerate transformative therapy to patients while maximizing shareholder value.' Stephen Chan, MD, PhD, Founder of Synhale, added, 'The unmet patient need in PH is immense, particularly in Groups 2 and 3, where heart failure with preserved ejection fraction (HFpEF) and chronic lung disease remain deadly and underserved. PH with HFpEF carriers a five-year mortality approaching 50%, with similarly grim outcomes in COPD and other lung diseases. By targeting glutaminase activity, we address a fundamental metabolic pathway across all PH groups, offering hope to patients with few options.' PH, a severe condition, is characterized by remodeling and stiffening in the pulmonary vasculature and often dramatically increases mortality risk when combined with other conditions. Current classifications fail to reflect the molecular drivers of PH, leaving treatment gaps. Synhale's approach with Telaglenastat targets elevated glutaminase activity, a key driver of vascular, cardiac, and pulmonary pathology, potentially benefiting not only rare Pulmonary Arterial Hypertension (Group 1) and chronic thromboembolic disease (Group 4) but also more prevalent PH linked to heart failure (Group 2) and chronic lung disease (Group 3). Telaglenastat, previously dosed in over 800 patients during oncology development, is Phase 2-ready with extensive preclinical data for PH. Synhale's clinical advancement strategy addresses an estimated $12B–$24B market opportunity across PH Groups 1-4. 'We are embarking on our next round of fundraising to advance Telaglenastat through critical clinical milestones,' added Holland. 'Our virtual operating model enables us to be capital-efficient while maintaining world-class expertise focused on delivering breakthrough therapies for PH patients.' About Synhale Therapeutics Synhale Therapeutics Inc. is a virtual biotech company dedicated to transforming Pulmonary Hypertension treatment by targeting elevated glutaminase activity—a key driver of vascular stiffness, fibrosis, and proliferation. Synhale's mission is to redefine PH treatment through mechanism-driven therapies that address the root cause of this disease. For Media & Investor Inquiries:Chad D. Hollandinfo@
Globe and Mail
12-03-2025
- Business
- Globe and Mail
Pulmonary Arterial Hypertension Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Pulmonary Arterial Hypertension Pipeline Insight' report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the Pulmonary Arterial Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Arterial Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Pulmonary Arterial Hypertension Treatment Landscape. Click here to read more @ Pulmonary Arterial Hypertension Pipeline Outlook Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report In March 2025:- United Therapeutics conducted a study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH). In March 2025:- Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg. In March 2025: Merck Sharp & Dohme LLC announced a study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to DelveInsight's Pulmonary Arterial Hypertension Pipeline analysis depicts a robust space with 55+ active players working to develop 55+ pipeline treatment therapies. The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others. Promising Pulmonary Arterial Hypertension Therapies such as TPN171H, Tadalafil, Treprostinil Palmitil, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept and others. Discover groundbreaking developments in Pulmonary Arterial Hypertension therapies! Gain in-depth knowledge of key Pulmonary Arterial Hypertension clinical trials, emerging drugs, and market opportunities @ Pulmonary Arterial Hypertension Clinical Trials Assessment Pulmonary Arterial Hypertension Emerging Drugs Profile Sotatercept: Acceleron Pharma Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH. LIQ861: Liquidia Technologies LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company's novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH). The Pulmonary Arterial Hypertension Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment. Pulmonary Arterial Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market Stay informed about the Pulmonary Arterial Hypertension pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Pulmonary Arterial Hypertension Unmet Needs Pulmonary Arterial Hypertension Companies Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others. Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical Molecule Type Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Transform your understanding of the Pulmonary Arterial Hypertension Pipeline! See the latest progress in drug development and clinical research @ Pulmonary Arterial Hypertension Market Drivers and Barriers, and Future Perspectives Scope of the Pulmonary Arterial Hypertension Pipeline Report Coverage- Global Pulmonary Arterial Hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others. Pulmonary Arterial Hypertension Therapies- TPN171H, Tadalafil, Treprostinil Palmitil, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept and others. Pulmonary Arterial Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Pulmonary Arterial Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Oncology Research–Access the Full Pulmonary Arterial Hypertension Pipeline Analysis Today! @ Pulmonary Arterial Hypertension Drugs and Companies Table of Content Introduction Executive Summary Pulmonary Arterial Hypertension: Overview Pipeline Therapeutics Therapeutic Assessment Pulmonary Arterial Hypertension – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Sotatercept: Acceleron Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) GB-002: Gossamer Bio Drug profiles in the detailed report….. Early Stage Products (Phase I) Apabetalone: Resverlogix Drug profiles in the detailed report….. Preclinical/Discovery Stage Products R107: Radikal Therapeutics Drug profiles in the detailed report….. Inactive Products Pulmonary Arterial Hypertension Key Companies Pulmonary Arterial Hypertension Key Products Pulmonary Arterial Hypertension- Unmet Needs Pulmonary Arterial Hypertension- Market Drivers and Barriers Pulmonary Arterial Hypertension- Future Perspectives and Conclusion Pulmonary Arterial Hypertension Analyst Views Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
